initial public offerings (IPOs) trading on American exchanges

Wednesday, October 11, 2017

Citius Pharmaceuticals (CTXR) issues shareholder letter


Citius Pharmaceuticals issues shareholder letter
Highlights of shareholder letter include: 
  • Successfully uplisted to Nasdaq stock exchange where the company will gain access to broader investor audience.
  • Received positive response from the FDA for phase 3 trial amendments of Mino-Lok, their proprietary product that address a potential $750 million sector.
  • Secured funding of more than $26.8 million, including a recent raise of $6.8 million, with significant insider participation.
  • Finalized the addition of South America to The Company's worldwide license for Mino-Lok.
  • Completed Phase 2a studies for Hydro-Lido, which could become the first FDA-approved product to address the estimated $500 million U.S. hemorrhoid marketplace.

10 months later

No comments:

Post a Comment